

National Research Ethics Service

North West 5 Research Ethics Committee - Haydock Park

NHS North West Room 155 - Gateway House Piccadilly South Manchester M60 7LP

Tel: 0161 237 2394 / 2152 Fax: 0161 237 2383

04 September 2009

Professor Deborah Symmons The University of Manchester arc Epidemiology Unit School of Medicine Oxford Road Manchester M13 9PT

Dear Professor Symmons

Study title: Prospective observational study of the long-term hazards

of anti-TNF therapy in rheumatiod arthritis

REC reference: 00/8/053 Amendment number: N/A

Amendment date: 14 August 2009

The above amendment was reviewed at the meeting of the Sub-Committee held on 25 August 2009.

Ethical opinion

RECEIVED

The British Society for Rheumatology Biologics Register (BSRBR) has been collecting data on patients receiving biologic therapy (including the anti-TNF drugs etanercept, infliximab and adalimumab) for rheumatoid arthritis (RA) during routine clinical care since 2001. One of the main reasons for setting up the study was to determine whether or not treatment with these drugs increased the risk of cancer, and in particular lymphoproliferative cancers including lymphoma. The amendment (dated 14 August 2009) sought approval for a number of changes to the current approved study protocol, as follows: -

- To ascertain the prevalence and incidence rates of patients with lymphoma who are already taking part in the BSRBR.
- To determine the subtypes of lymphoma in the biologics cohort by reclassifying them in accordance with the World Health Organisation classification.
- 3. To examine the factors predicting development and outcome of lymphoma in the biologics treated cohort, and in particular the influence of disease activity.

There are currently 49 patients registered with the BSRBR, who have been treated with biologic drugs for RA and had been diagnosed with lymphoma during the course of the study. It was anticipated that this number would increase as patients continued to be followed via the registry.

A comprehensive, clear and well written rationale had been submitted in support of the amendment.

The Sub-Committee had no ethical difficulties with the proposed amendment.

The members of the Committee taking part in the review gave a favourable ethical opinion of the amendment on the basis described in the notice of amendment form and supporting documentation.

Approved documents

The documents reviewed and approved at the meeting were:

Version	Date
1	14 August 2009
	14 August 2009
1	10 August 2009
	Version 1 1 1 1 1 1 1 1 1 1

Membership of the Committee

The members of the Committee who took part in the review are listed on the attached sheet.

R&D approval

All investigators and research collaborators in the NHS should notify the R&D office for the relevant NHS care organisation of this amendment and check whether it affects R&D approval of the research.

Statement of compliance

The Committee is constituted in accordance with the Governance Arrangements for Research Ethics Committees (July 2001) and complies fully with the Standard Operating Procedures for Research Ethics Committees in the UK.

00/8/053:

Please quote this number on all correspondence

Yours sincerely

Noel Graham

Committee Co-ordinator

E-mail:

noel.graham@northwest.nhs.uk

Enclosures:

List of names and professions of members who took part in the review

North West 5 Research Ethics Committee - Haydock Park

Attendance at Sub-Committee meeting on 25 August 2009

Name	Profession	Capacity
Dr Tim Sprosen	Medical Researcher / Epidemiologist	Expert
Professor Caroline Carlisle	Professor of Education in Nursing and Midwifery – The University of Manchester	Expert

Written comments received from:

Name	Position
Mr Alan Rigby	Medical Statistician

In attendance:

Name	Position
Mr Noel Graham	REC Co-ordinator

Copy to:

Dr Karen Shaw

Head of University Research Office University of Manchester Oxford Road Manchester M13 9PL